$1 184.70
In stock
Guaranteed refund or reship if you haven't received your order
Secure and encrypted payment processing
We ship to over 40 countries including the USA, UK, Europe, Australia and Japan

Pharmacological properties

Votrient is an oral agent, a powerful polyarget inhibitor of vascular endothelial growth factor receptors (vegfr) -1, -2 and -3, platelet-derived growth factor receptors (pdgfr) -α and β and stem cell factor receptors (c-kit) for which the ic50 of the drug is 10; thirty; 47; 71; 84 and 74 nmol / ml, respectively. in preclinical experimental studies, pazopanib dose-dependently inhibited ligand-induced autophosphorylation of vegfr-2, c-kit and pdgfr-β receptors in cells. in an in vivo study, pazopanib inhibited vegf-induced vegfr-2 phosphorylation in animal lungs, animal angiogenesis in various experimental models, and the growth of multiple xenografts of human tumor in animals.

Pharmacokinetics Absorption. Pazopanib is absorbed with the median time required to reach Cmax the drug in the blood, 2-4 hours after ingestion. A daily intake of the drug causes an increase in AUC of 1.23-4 times. With an increase in the dose of Votrient over 800 mg, a corresponding increase in AUC and Cmax missing.

Systemic absorption of pazopanib is increased when taken with food. Eating, depending on high or low fat, causes an increase in AUC and Cmax Votrienta about 2 times. Based on this, Votrient should be taken at least 1 hour before or 2 hours after a meal (see APPLICATION).

When taking one crushed tablet of pazopanib 400 mg AUC(0–72) increased by 46%, Cmax - about 2 times, and also Tmax decreased by about 1.5 hours compared with taking a whole tablet of the drug. These data indicate that the bioavailability of pazopanib and its level of absorption after oral administration increase when taking a crushed tablet compared to taking a whole tablet of the drug. Therefore, taking into account such a possible increase in the absorption of the drug, Votrient tablets should not be crushed (see APPLICATION).

Distribution. The binding of pazopanib to plasma proteins in humans in vivo is more than 99%, regardless of the concentration of the drug in the blood within the range of 10–100 μg / ml. In vitro studies have shown that pazopanib is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP).

Metabolism. In vitro studies have shown that pazopanib metabolism provides predominantly CYP 3A4 with little involvement of CYP 1A2 and CYP 2C8.

Elimination. Pazopanib is excreted slowly, medium T½ is 30.9 hours after taking the recommended dose of 800 mg. Elimination of the drug occurs mainly with feces, while 4% of the accepted dose is excreted in the urine.

Indications

Treatment of locally advanced and / or metastatic renal cell carcinoma (PCC).

Treatment of patients with advanced soft tissue sarcoma who have previously received chemotherapy, with the exception of patients with gastrointestinal stromal tumor or liposarcoma.

Application

The recommended dose of the Votrient preparation for the treatment of patients with PCD and soft tissue sarcoma is 800 mg once a day orally. treatment lasts until disease progresses or intolerable toxicity.

Votrient should be taken between meals (at least 1 hour before or 2 hours after eating) (see Pharmacokinetics).

Votrient should be swallowed without chewing and washed down with water, making sure that the tablet is not broken or crushed (see Pharmacokinetics).

If the next dose is missed, the tablet should not be taken less than 12 hours before the next dose.

Dose modification. In order to control adverse reactions or in case of increased individual sensitivity to the drug, dose modification is possible. Dosing changes - both with increasing and decreasing doses - are carried out in stages, with a step of 200 mg, taking into account the individual tolerance of the drug, to ensure proper control of adverse reactions. The dose of Votrient should not exceed 800 mg.

Special patient groups

Renal failure.To date, there is no experience with the use of the drug in patients with severe renal failure or those on peritoneal dialysis or hemodialysis, therefore, Votrient is not recommended for such patients. Renal failure should not have a clinically significant effect on the pharmacokinetics of pazopanib, taking into account the low level of excretion of pazopanib and its metabolites through the kidneys, and dose adjustment is not required for patients with creatinine clearance ≥30 ml / min (see Pharmacokinetics).

Liver failure. The safety of pazopanib and its pharmacokinetics in patients with hepatic impairment have not been sufficiently studied to date (see SPECIAL INSTRUCTIONS).

Patients with mild hepatic insufficiency, which is determined by the level of aminotransferase (AlAT) and bilirubin, do not need to change the dose (see PHARMACOLOGICAL PROPERTIES).

In patients with moderate liver dysfunction, the dose of Votrient should be reduced to 200 mg / day. To date, there is insufficient data on the use of the drug in patients with severe hepatic insufficiency (total bilirubin is more than 3 times higher than the upper limit of normal (VGN), regardless of the level of ALAT), therefore, the appointment of Votrient is not recommended for such patients.

Elderly patients. Patients over the age of 65 do not need to adjust the dose, frequency and method of taking the drug.

Contraindications

Hypersensitivity to any component of the drug.

Side effects

The following are adverse reactions in accordance with the classification "system - organ - class" meddra. the following conventions were used to classify by the frequency of occurrence: very often (≥1 / 10), often (≥1 / 100, 1/10), infrequently (≥1 / 1000, 1/100), rarely (≥1 / 10 000 , 1/1000).

Categories are determined based on the absolute incidence of adverse reactions according to clinical studies.

Organs and systems Frequency
PAC Soft tissue sarcoma
Infections and infestations
Infections (with or without neutropenia) * Infrequently **
Gum infections ** Often
From benign neoplasms, malignant and nonspecific (including cysts and polyps)
Tumor pain ** Often
On the part of the blood and lymphatic system
Neutropenia Often Often
Thrombocytopenia Often Often
Leukopenia Often Often
Thrombotic microangiopathy (including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome) * Rarely Rarely
Endocrine system
Hypothyroidism Often Often
Metabolic and nutritional disorders
Decreased appetite, including anorexia Often Often
Hyperalbuminemia ** Often
Dehydration ** Often
Hypophosphatemia Infrequently **
Hypomagnesemia Infrequently Infrequently
Mental disorders
Insomnia ** Often
From the nervous system
Dizziness Often Often
Dysgeusia (including agevzia and hypogevzia) Often Often
Headache Often Often
Lethargy Often **
Paresthesia Often Infrequently
Peripheral Sensory Neuropathy Infrequently Often
Hypesthesia Infrequently **
Ischemic stroke Infrequently Infrequently
Transient Ischemic Attacks Infrequently **
Cerebral infarction Infrequently Infrequently
Drowsiness ** Infrequently
Posterior Reverse Encephalopathy / Posterior Reverse Leukoencephalopathy * Rarely **
On the part of the organ of vision
Discoloration of the eyelids Infrequently **
Visual impairment ** Often
From the heart
Heart dysfunction (left ventricular dysfunction, heart failure, obstructive cardiomyopathy) Infrequently Often
Bradycardia Infrequently Often
Myocardial infarction Infrequently Infrequently
Myocardial ischemia Infrequently **
From the vessels
Ag Often Often
Venous thromboembolic complications (including deep vein thrombosis, pulmonary thrombosis) Infrequently Often
The tides Often Often
Flushing (redness of the face) Infrequently Often
Bleeding Infrequently Infrequently
Hypertensive crisis Infrequently
From the respiratory system
Cough ** Often
Dysphonia Often Often
Nosebleeds Often Often
Pulmonary embolism Infrequently
Hemoptysis Infrequently Infrequently
Pulmonary hemorrhage Infrequently Often
Dyspnoea ** Often
Pneumothorax ** Often
Hiccups ** Often
Oropharyngeal pain ** Infrequently
Bronchial bleeding ** Infrequently
Rhinorrhea ** Infrequently
From the digestive system
Diarrhea Often Often
Nausea Often Often
Vomiting Often Often
Abdominal pain Often Often
Dyspepsia Often Often
Stomatitis Often Often
Flatulence Often Often
Bloating Often Often
Dry mouth ** Often
Oral ulcers Infrequently **
Frequent bowel movements Infrequently **
Gastrointestinal bleeding Infrequently Infrequently
Rectal bleeding Infrequently Infrequently
Anal bleeding ** Often
Colon perforation Infrequently **
Oral bleeding Infrequently Often
Gastrointestinal fistula Infrequently Infrequently
Vomiting blood Infrequently **
Feces with blood Infrequently **
Hemorrhoidal bleeding Infrequently **
Ileum perforation Infrequently Infrequently
Melena Infrequently Infrequently
Esophagus bleeding Infrequently Infrequently
Pancreatitis * Infrequently **
Peritonitis Infrequently Infrequently
Retroperitoneal bleeding Infrequently Infrequently
Bleeding from the upper gastrointestinal tract Infrequently Infrequently
On the part of the liver and biliary tract
Impaired liver function Often Infrequently
Hyperbilirubinemia Often **
Hepatotoxicity Infrequently **
Jaundice Infrequently **
Hepatitis Infrequently **
Liver failure Infrequently **
On the part of the skin and its derivatives
Hair color change Often Often
Rash Often Infrequently
Alopecia Often Often
Palmar-plantar erythrodysesthesia syndrome Often Infrequently
Hypopigmentation of the skin Often Often
Erythema Often Often
Itching Often Often
Skin depigmentation Often Often
Dry skin ** Often
Hyperhidrosis Often Often
Photosensitivity Reactions Infrequently Infrequently
Exfoliative rash Infrequently Often
Hair depigmentation Often Often
Violations of the nails ** Often
Vesicular rash Infrequently **
Papular rash Infrequently Infrequently
Erythematous rash Infrequently **
Generalized rash Infrequently **
Macular rash Infrequently **
Itchy rash Infrequently **
Generalized itching Infrequently **
Erythema palms Infrequently **
Skin ulcers ** Infrequently
From the musculoskeletal system and connective tissue
Pain in the organs of the musculoskeletal system ** Often
Myalgia Often Often
Muscle spasms Often Often
Arthralgia Infrequently
From the kidneys and urinary system
Proteinuria Often Infrequently
Urinary tract bleeding Infrequently **
From the reproductive system and mammary glands
Menorrhagia Infrequently Infrequently
Metrorrhagia Infrequently **
Vaginal bleeding Infrequently Infrequently
General violations
Fatigue Often Often
Asthenia Often Infrequently
Mucosal inflammation Often Infrequently
Edema (peripheral edema, eye edema, localized edema and facial edema) Often Often
Chest pain Often Often
Chills ** Often
Mucosal disorders Infrequently **
Laboratory test data
Increased ALAT Often Often
Increased AsAT Often Often
Body weight reduction Often Often
Changes in the level of cholesterol in the blood ** Often
Increased Blood Creatinine Often
Blood bilirubin increase Often Often
Decreased white blood cell count, including decreased neutrophils and white blood cells Often **
Platelet lowering Infrequently Infrequently
Decreased blood lipase levels Often **
Increase in blood pressure Often **
Thyroid hormone levels Often **
Increased Gamma Glutamyl Transferase Levels Often Often
Increased blood urea Infrequently **
ECG Q-T interval extension Infrequently Infrequently
Increased blood amylase Infrequently **
Increased blood glucose Infrequently **
Increased transaminase levels Infrequently **
Increased diastolic blood pressure Infrequently **
Thyroid abnormal tests Infrequently **
Increased systolic blood pressure Infrequently **
Abnormal liver function tests Infrequently **

* Side effects according to post-marketing applications.

** Side effects are not considered to be associated with the use of pazopanib in a pilot clinical trial for this indication.

special instructions

Effect on the liver. There are reports of cases of the development of liver failure (including fatal outcome) with the use of the drug vientent. during clinical trials, against the background of the use of the drug, an increase in the level of transaminases (alat, asat) and bilirubin was noted (see side effects). in most cases, an isolated increase in the levels of alat and asat was recorded without a concomitant increase in the levels of alkaline phosphatase or bilirubin. in the vast majority of cases (90%), an increase in the level of transaminases of any severity developed in the first 18 weeks of using the drug.

It is necessary to determine the levels of hepatic enzymes in blood plasma before treatment with Votrient and at least every 4 weeks during the first 4 months of treatment with the drug, as well as in the presence of clinical indications. In the future, these indicators should also be periodically monitored.

For patients with the initial (before treatment with the drug) level of total bilirubin is ≤1.5 times higher than VGN and AsAT, AlAT ≤2 times higher than VGN, one should adhere to the following recommendations for the use of the drug:

  • patients with an isolated increase in ALAT levels in the range from 3 to ≤8 above VGN can continue treatment with Votrient subject to weekly monitoring of liver function until the level of ALAT decreases to I degree or returns to the initial level.
  • Patients with ALAT 8 above VGN should stop taking Votrient until the level of this indicator drops to grade I or returns to the initial level. If the potential benefits of re-taking Votrient are regarded as predominant over the risk of developing manifestations of hepatotoxicity of the drug, you can again start Votrient treatment at a low dose (400 mg once a day), while monitoring the level of plasma liver enzymes weekly for 8 weeks (see APPLICATION). If, after repeated use of Votrient, an increase in the level of AlAT 3 above VGN is again noted, it is necessary to permanently cancel the drug.
  • If an increase in the level of AlAT 3 above VGN is noted simultaneously with an increase in the level of bilirubin 2 above VGN, it is necessary to permanently cancel Votrient. In such patients, it is necessary to monitor these indicators until they decrease to I degree or return to the original value. Pazopanib is an UGT inhibitor1A1. In patients with Gilberts syndrome, with the use of the drug, mild hyperbilirubinemia due to indirect (unbound) bilirubin may develop. Management of patients only with mild indirect hyperbilirubinemia, previously diagnosed with Gilberts syndrome or in the presence of suspicion of it and an increase in the level of ALAT 3 above VGN should be carried out in accordance with the recommendations given for cases in isolation

Tags: Votrient® [Pazopanib]